Literature DB >> 21262360

Estrogen receptor β signaling regulates the progression of Chinese non-small cell lung cancer.

Guangfeng Zhao1, Shuli Zhao, Tingting Wang, Shihua Zhang, Kaihua Lu, Like Yu, Yayi Hou.   

Abstract

Prospective studies have found that the risk of non-small cell lung cancer (NSCLC) has close relationship with estrogen. The effects of estrogens are mediated via two estrogen receptor (ER) isoforms, that is, ER alpha (ERα) and ER beta (ERβ). ERα in NSCLC has been evaluated mostly by immunohistochemistry. However, our previous study showed that ERβ was also highly expressed in Chinese NSCLC. But the roles of ERβ in Chinese NSCLC have not been clarified as yet. So in the present study, two Chinese lung adenocarcinoma cell lines, SPC-A1 and LTEP-a2, were used and the role of ERβ in lung tumorigenesis was focused to be investigated by in vitro and in vivo experiments. The results showed that over-expressed ERβ can promote the development of NSCLC, while siRNAs targeting ERβ gene can inhibit growth of NSCLC cells and induce apoptosis of these cells via mitochondrial depolarization and caspase-3 activation. These results indicated that ERβ plays an important role in development of Chinese NSCLC. This suggests that ERβ deactivation or down-regulation may possess potential therapeutic utility for the treatment of lung cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262360     DOI: 10.1016/j.jsbmb.2011.01.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.

Authors:  Jing Ren; Yunzhong Nie; Mingming Lv; Sunan Shen; Ruijing Tang; Yujun Xu; Yayi Hou; Shuli Zhao; Tingting Wang
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

2.  Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β.

Authors:  Hexiao Tang; Yongde Liao; Guang Chen; Liqiang Xu; Chao Zhang; Sheng Ju; Sheng Zhou
Journal:  Med Oncol       Date:  2012-03-17       Impact factor: 3.064

3.  Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis.

Authors:  Hye-Ryoun Kim; Seo Yun Kim; Cheol Hyeon Kim; Sung Hyun Yang; Jae Cheol Lee; Chang-Min Choi; Im Il Na
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-08       Impact factor: 4.553

4.  The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer.

Authors:  Zhaoguo Liu; Yongde Liao; Hexiao Tang; Guang Chen
Journal:  Endocrine       Date:  2013-03-10       Impact factor: 3.633

5.  The co-expression of ERβ2 and IL-12Rβ2 is better prognostic factor in non-small-cell lung cancer progression.

Authors:  Zhao-Guo Liu; Yi-Yan Lei; Wen-Wen Li; Zhen-Guang Chen
Journal:  Med Oncol       Date:  2013-05-16       Impact factor: 3.064

6.  ERβ-mediated estradiol enhances epithelial mesenchymal transition of lung adenocarcinoma through increasing transcription of midkine.

Authors:  Guangfeng Zhao; Yunzhong Nie; Mingming Lv; Lingfang He; Tingting Wang; Yayi Hou
Journal:  Mol Endocrinol       Date:  2012-06-05

Review 7.  [Advances of targeted therapy based on estrogen receptor signaling pathway in lung cancer].

Authors:  Liqiang Xu; Yongde Liao; Hexiao Tang; Chao Zhang; Zhaoguo Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-09

8.  CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.

Authors:  Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan
Journal:  Cell Commun Signal       Date:  2020-09-17       Impact factor: 5.712

9.  Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression.

Authors:  Hexiao Tang; Yongde Liao; Chao Zhang; Guang Chen; Liqiang Xu; Zhaoguo Liu; Shengling Fu; Li Yu; Sheng Zhou
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.